Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Etoricoxib in Acute Soft Tissue Rheumatism Affecting the Shoulder.

Next Previous
Search
Trial Profile

Efficacy and Safety of Etoricoxib in Acute Soft Tissue Rheumatism Affecting the Shoulder.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 10 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etoricoxib (Primary)
  • Indications Musculoskeletal pain; Rheumatic disorders
  • Focus Therapeutic Use

    • Most Recent Events

    • 02 Jul 2012 Actual patient number is 45 according to ClinicalTrials.gov.
    • 02 Jul 2012 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
    • 02 Jul 2012 Drug company (Merck) added to the associations as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top